MSWM
BMRN icon

Mowery & Schoenfeld Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mowery & Schoenfeld Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$11.9K – 376
2025
Q4 		$11.9K Buy
+200
New +$10.9K 0.02% 228

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mowery & Schoenfeld Wealth Management's BMRN Position: Q1 2026 in Review

Mowery & Schoenfeld Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 200 shares — an estimated $11.9K sold.

Mowery & Schoenfeld Wealth Management first reported a position in BMRN in Q4 2025 and held it in 1 quarter. The position peaked at $11.9K in Q4 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Mowery & Schoenfeld Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mowery & Schoenfeld Wealth Management sold 200 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $11.9K.
  • Mowery & Schoenfeld Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Mowery & Schoenfeld Wealth Management's BioMarin Pharmaceuticals position peaked at $11.9K in Q4 2025.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Mowery & Schoenfeld Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.